Annual Meeting Clinical Trials Plenary Session, Sanofi presented data on tolebrutinib in patients with non-relapsing ...

The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) has approved ...

Sanofi’s tolebrutinib has been shown to delay disability progression in multiple sclerosis (MS) patients, according to phase ...

Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis Results from the HERCULES phase 3 study showed delay in disability progression in people ...

At the American Academy of Neurology (AAN) 2025 Annual Meeting Clinical Trials Plenary Session, Sanofi presented data on tolebrutinib in patients with non-relapsing secondary progressive multiple ...

Tolebrutinib was found to delay disability progression in people with nonrelapsing secondary progressive MS in a Phase 3 ...

SAN DIEGO -- Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive ...

The New England Journal of Medicine published results from the HERCULES phase 3 study demonstrating that tolebrutinib delayed disability ...

Sanofi announces tolebrutinib phase 3 study data published in NEJM shows benefit on disability progression in multiple sclerosis: Paris Thursday, April 10, 2025, 10:00 Hrs [IST] T ...